- Home
- GHRS
GHRS
GH Research PLC
as 04-18-2025 1:36pm EST
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.
| Founded: | 2018 | Country: | Ireland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 868.7M | IPO Year: | 2021 |
| Target Price: | $30.86 | AVG Volume (30 days): | 208.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.75 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.00 - $20.50 | Next Earning Date: | 05-02-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest GH Research PLC News
GHRS Breaking Stock News: Dive into GHRS Ticker-Specific Updates for Smart Investing
TipRanks
a month ago
Psychedelic: Exclusive talk with biotech company Clearmind Medicine
TipRanks
a month ago
Psychedelic: atai Life Sciences, NRx report quarterly results
TipRanks
a month ago
Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial
TipRanks
a month ago
Guggenheim starts GH Research at Buy, sees long-term upside potential
MT Newswires
a month ago
Guggenheim Initiates GH Research at Buy With $32 Price Target
MT Newswires
a month ago
RBC Initiates GH Research at Outperform, Speculative Risk With $31 Price Target
Insider Monkey
2 months ago
Why GH Research PLC (GHRS) is Skyrocketing So Far in 2025
Insider Monkey
2 months ago
GH Research PLC (GHRS): Among the Best Psychedelic Stocks to Buy in 2025
Compare GHRS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GHRS GH Research PLC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.